Literature DB >> 31763974

Progress in the Mechanism and Clinical Application of Cilostazol.

Huilei Zheng1,2,3, Hua Yang2,3,4, Danping Gong2,3,5, Lanxian Mai2,3,6, Xiaoling Qiu2,3, Lidai Chen2,3, Xiaozhou Su2,3, Ruoqi Wei7, Zhiyu Zeng2,3,5.   

Abstract

Cilostazol is a unique platelet inhibitor that has been used clinically for more than 20 years. As a phosphodiesterase type III inhibitor, cilostazol is capable of reversible inhibition of platelet aggregation and vasodilation, has antiproliferative effects, and is widely used in the treatment of peripheral arterial disease, cerebrovascular disease, percutaneous coronary intervention, etc. This article briefly reviews the pharmacological mechanisms and clinical application of cilostazol. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  ADP; Anti-platelet aggregation; Antiplatelet drugs; Cilostazol; Clinical application; Mechanism.

Mesh：

Substances：

Year:  2019        PMID： 31763974     DOI： 10.2174/1568026619666191122123855

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN： 1568-0266            Impact factor:   3.295


  4 in total

Review 1.  Research progress of phosphodiesterase inhibitors in inflammatory bowel disease treatment.

Authors:  Jianrong Shi; Wangqian Ma; Huifang Tang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-10-25

2.  Effect of Baicalein on the Pharmacokinetics of Cilostazol and Its Two Metabolites in Rat Plasma Using UPLC-MS/MS Method.

Authors:  Qinghua Weng; Chaojie Chen; Jianhua Xiong; Ya-Nan Liu; Xinxin Pan; Ju Cui; Jian-Ping Cai; Ren-Ai Xu
Journal:  Front Pharmacol       Date:  2022-04-27       Impact factor: 5.988

3.  Efficacy and Safety of Adjunctive Cilostazol to Clopidogrel-Treated Diabetic Patients With Symptomatic Lower Extremity Artery Disease in the Prevention of Ischemic Vascular Events.

Authors:  Kallirroi Kalantzi; Nikolaos Tentolouris; Andreas J Melidonis; Styliani Papadaki; Michail Peroulis; Konstantinos A Amantos; George Andreopoulos; George I Bellos; Dimitrios Boutel; Magdalini Bristianou; Dimitrios Chrisis; Nikolaos A Dimitsikoglou; John Doupis; Chrysoula Georgopoulou; Stergios A Gkintikas; Styliani Iraklianou; Κonstantinos Kanellas; Kalliopi Kotsa; Theocharis Koufakis; Maria Kouroglou; Anastasios G Koutsovasilis; Leonidas Lanaras; Eirini Liouri; Charalampos Lixouriotis; Akrivi Lykoudi; Efthymia Mandalaki; Evanthia Papageorgiou; Nikolaos Papanas; Spyridon Rigas; Maria I Stamatelatou; Ioannis Triantafyllidis; Aikaterini Trikkalinou; Aikaterini N Tsouka; Ourania Zacharopoulou; Christos Zoupas; Ioannis Tsolakis; Alexandros D Tselepis
Journal:  J Am Heart Assoc       Date:  2020-12-17       Impact factor: 5.501

4.  Cilostazol combined with P2Y12 receptor inhibitors: A substitute antiplatelet regimen for aspirin-intolerant patients undergoing percutaneous coronary stent implantation.

Authors:  Yikai Zhao; Peng Zhou; Wen Gao; Haoxuan Zhong; Yufei Chen; Wei Chen; Maieryemu Waresi; Kun Xie; Haiming Shi; Hui Gong; Guibin He; Zhaohui Qiu; Xinping Luo; Jian Li
Journal:  Clin Cardiol       Date:  2022-02-04       Impact factor: 2.882
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.